drugset / Trial / NCT01193491
Dose Escalation of IPI-493 in Hematologic Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, determine the maximum tolerated dose (MTD) and schedule of IPI-493 in patients with hematologic malignancies.
Timeline
- Start
- 2010-06
- Primary completion
- 2011-07
- Completion
- 2011-07
Outcome
Outcome not reported
Stopped: “Drug exposure of retaspimycin HCl was superior to IPI-493, Infinity will focus on Retaspimycin HCL”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IPI-493 | Unknown | — | — |